Myovant Sciences Ltd news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

MYOV 13.79 -0.12 (-0.86%)
price chart
Myovant Sciences (MYOV) Presents at Baird's 2017 Global Healthcare Conference ...
So who is Myovant Sciences? This is a company that was created with a vision, a vision to become a global leader in women's health and endocrine diseases.
Trading Update: ABR in Focus for Myovant Sciences Ltd. (:MYOV)
Investors have the ability to track Wall Street analyst opinions in order to assist with stock research. Analysts often provide Buy, Sell, or Hold recommendations ratings for companies that they cover.
Myovant Sciences Secures Flexible Financing Commitments of up to $140 Million
BASEL, Switzerland, Oct. 16, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced that it has secured up to $140 million in flexible financing commitments from NovaQuest Capital Management ("NovaQuest") and Hercules Capital, Inc. (NYSE ...
Myovant Bolsters Executive Team with Key Management Appointments
Mr. Lang was previously Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences, Inc. At Gilead, in addition to leading core functions within the legal department, Mr. Lang was a member of ...
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 ...
BASEL, Switzerland, Oct. 2, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced that Takeda Pharmaceutical Company Limited ("Takeda") has reported positive top-line results from a Phase 3 study evaluating the efficacy and safety of ...
Myovant Sciences Provides Corporate Update and Reports Financial Results for ...
R&D expenses for the three months ended September 30, 2017 consisted primarily of clinical trial and clinical drug supply costs of $19.7 million, personnel expenses of $3.0 million, share-based compensation expense of $0.7 million, and costs billed to ...
Myovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep ...
BASEL, Switzerland, Nov. 21, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that ...
Myovant Sciences Provides Corporate Update and Reports Financial Results for ...
In June 2017, Myovant announced the initiation of a Phase 3 clinical program consisting of two randomized, double-blind, placebo-controlled, international clinical trials, SPIRIT 1 and SPIRIT 2, to evaluate relugolix in women with endometriosis ...
Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with ...
"With the initiation of the SPIRIT program, Myovant will be running five ongoing Phase 3 trials for relugolix in three critical areas of unmet medical need," said Lynn Seely, MD, President & Chief Executive Officer of Myovant Sciences, Inc. "I could ...
Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix ...
BASEL, Switzerland, May 7, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced the presentation of data from a placebo-controlled Phase 2 dose-finding study conducted by Takeda Pharmaceutical Company Ltd. in Japan evaluating the ability ...